Last 47 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Merck & Co., Inc.'s quarterly P/E stands at 22.1x, up 31.6% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has compressed 31.1% YoY to 8.6x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 15.64 | 22.11 | 9.04 | 11.24 | 11.16 | 16.80 | 22.90 | 14.46 | 17.64 | — | 13.84 | — | 23.96 |
| — | +31.6% | -60.5% | -22.3% | -36.7% | — | +65.5% | — | -26.4% | — | -17.7% | — | +98.6% | |
| P/S Ratio | 4.33 | 4.01 | 3.05 | 3.15 | 3.64 | 4.04 | 4.33 | 4.89 | 5.32 | 4.76 | 4.11 | 4.87 | 4.68 |
| — | -0.8% | -29.6% | -35.6% | -31.6% | -15.0% | +5.5% | +0.3% | +13.6% | -6.9% | +12.2% | +22.8% | +43.1% | |
| P/B Ratio | 5.42 | 4.97 | 4.04 | 4.05 | 4.69 | 5.45 | 6.48 | 7.22 | 8.30 | 7.40 | 6.35 | 7.56 | 5.79 |
| — | -8.8% | -37.6% | -43.8% | -43.5% | -26.3% | +2.0% | -4.6% | +43.5% | +20.5% | +29.1% | +41.5% | +13.8% | |
| P/FCF | 22.75 | 35.89 | 7.67 | 19.66 | 48.46 | 25.15 | 8.48 | 16.25 | 37.65 | — | 9.62 | 26.74 | 204.37 |
| — | +42.7% | -9.6% | +21.0% | +28.7% | — | -11.8% | -39.2% | -81.6% | — | -21.4% | +46.6% | +1383.3% | |
| EV / EBITDA | 10.82 | 8.63 | 6.82 | 7.63 | 8.11 | 12.53 | 15.09 | 11.76 | 13.51 | — | 10.47 | — | 15.24 |
| — | -31.1% | -54.8% | -35.1% | -39.9% | — | +44.2% | — | -11.4% | — | -11.0% | — | +77.6% | |
| EV / EBIT | 13.51 | 12.09 | 7.80 | 8.90 | 9.44 | 15.44 | 17.65 | 13.51 | 15.25 | — | 12.14 | — | 18.78 |
| — | -21.7% | -55.8% | -34.2% | -38.1% | — | +45.4% | — | -18.8% | — | -22.0% | — | +65.7% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Merck & Co., Inc.'s operating margin was 37.7% in Q4 2025, down 5.7 pp QoQ and up 9.9 pp YoY. The trailing four-quarter average of 41.1% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 6.6% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.0% | 70.5% | 75.6% | 75.7% | 75.1% | 75.5% | 75.5% | 76.8% | 77.6% | 73.3% | 73.3% | 73.2% | 72.9% |
| — | -6.6% | +0.1% | -1.4% | -3.1% | +3.1% | +3.0% | +4.8% | +6.4% | +1.8% | -0.6% | +3.0% | +10.2% | |
| Operating Margin | 36.2% | 37.7% | 43.4% | 40.2% | 43.0% | 27.8% | 23.9% | 38.0% | 36.5% | -11.7% | 36.8% | -33.3% | 26.3% |
| — | +35.6% | +81.6% | +5.8% | +17.7% | +337.7% | -35.0% | +214.1% | +39.0% | -146.4% | +34.0% | -196.0% | -25.7% | |
| Net Margin | 28.1% | 18.2% | 33.7% | 28.0% | 32.5% | 24.0% | 19.0% | 33.9% | 30.2% | -8.4% | 29.7% | -39.7% | 19.5% |
| — | -24.2% | +77.6% | -17.2% | +7.7% | +385.9% | -36.2% | +185.2% | +55.0% | -138.4% | +36.9% | -247.0% | -28.2% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 36.9% | 5.7% | 11.5% | 9.1% | 10.7% | 8.2% | 7.2% | 13.0% | 12.2% | -3.1% | 11.9% | -14.0% | 6.1% |
| — | -31.2% | +60.1% | -30.0% | -12.2% | +365.0% | -39.6% | +193.0% | +101.0% | -146.6% | +60.3% | -249.1% | -44.2% | |
| ROA | 14.4% | 2.2% | 4.7% | 3.8% | 4.4% | 3.2% | 2.7% | 5.0% | 4.5% | -1.1% | 4.5% | -5.6% | 2.6% |
| — | -30.3% | +70.7% | -23.8% | -2.4% | +377.7% | -38.9% | +188.7% | +72.3% | -141.2% | +48.2% | -252.6% | -35.9% | |
| ROIC | 22.0% | 5.6% | 7.4% | 6.3% | 6.9% | 4.7% | 4.3% | 6.6% | 6.3% | -1.9% | 6.4% | -5.5% | 4.3% |
| — | +20.7% | +70.8% | -4.4% | +8.6% | +344.9% | -32.5% | +221.2% | +48.2% | -147.1% | +34.2% | -192.9% | -34.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Merck & Co., Inc.'s Debt/EBITDA ratio is 5.9x, up from 4.8x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 12.6% YoY to 1.54x, strengthening the short-term liquidity position. Debt/Equity has risen for 4 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.96 | 0.96 | 0.80 | 0.72 | 0.72 | 0.83 | 0.86 | 0.87 | 0.85 | 0.96 | 0.84 | 0.95 | 0.66 |
| — | +16.3% | -6.9% | -16.6% | -15.0% | -14.4% | +1.4% | -9.1% | +29.1% | +38.8% | +23.5% | +30.3% | -15.6% | |
| Debt / EBITDA | 1.72 | 5.86 | 4.85 | 4.77 | 4.46 | 6.90 | 7.38 | 5.20 | 5.07 | — | 5.06 | — | 6.41 |
| — | -15.1% | -34.3% | -8.3% | -12.1% | — | +45.7% | — | -20.8% | — | -15.7% | — | +35.9% | |
| Current Ratio | 1.54 | 1.54 | 1.66 | 1.42 | 1.41 | 1.36 | 1.36 | 1.47 | 1.25 | 1.25 | 1.38 | 1.28 | 1.44 |
| — | +12.6% | +21.8% | -2.9% | +12.6% | +9.0% | -1.4% | +14.4% | -13.2% | -15.0% | -5.2% | -7.6% | +3.3% | |
| Quick Ratio | 1.30 | 1.30 | 1.44 | 1.17 | 1.16 | 1.15 | 1.15 | 1.22 | 0.99 | 1.00 | 1.12 | 1.03 | 1.19 |
| — | +13.2% | +24.5% | -3.9% | +17.2% | +14.4% | +3.1% | +18.5% | -16.6% | -18.3% | -8.0% | -10.4% | +4.6% | |
| Interest Coverage | 17.31 | 14.99 | 22.82 | 20.85 | 21.44 | 13.71 | 13.39 | 20.37 | 19.71 | -5.60 | 18.73 | -18.26 | 16.08 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Deep dive into MRK consensus models and risk factors.
Wall Street verdict, signals, and target summaries.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MRK stock.
Merck & Co., Inc.'s current P/E is 15.6x. The average P/E over the last 4 quarters is 13.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Merck & Co., Inc.'s current operating margin is 36.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Merck & Co., Inc.'s business trajectory between earnings reports.